Parathyroid neoplasms refer to abnormal growths in the parathyroid glands, which are small endocrine glands located in the neck, near or within the thyroid gland. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign parathyroid neoplasms are typically called parathyroid adenomas and are the most common type of parathyroid disorder. They result in overproduction of parathyroid hormone (PTH), leading to a condition known as primary hyperparathyroidism. Symptoms may include kidney stones, osteoporosis, fatigue, depression, and abdominal pain.

Malignant parathyroid neoplasms are called parathyroid carcinomas. They are rare but more aggressive than adenomas, with a higher risk of recurrence and metastasis. Symptoms are similar to those of benign neoplasms but may also include hoarseness, difficulty swallowing, and enlarged lymph nodes in the neck.

It is important to note that parathyroid neoplasms can only be definitively diagnosed through biopsy or surgical removal and subsequent histopathological examination.

Parathyroid hormone (PTH) is a polypeptide hormone that plays a crucial role in the regulation of calcium and phosphate levels in the body. It is produced and secreted by the parathyroid glands, which are four small endocrine glands located on the back surface of the thyroid gland.

The primary function of PTH is to maintain normal calcium levels in the blood by increasing calcium absorption from the gut, mobilizing calcium from bones, and decreasing calcium excretion by the kidneys. PTH also increases phosphate excretion by the kidneys, which helps to lower serum phosphate levels.

In addition to its role in calcium and phosphate homeostasis, PTH has been shown to have anabolic effects on bone tissue, stimulating bone formation and preventing bone loss. However, chronic elevations in PTH levels can lead to excessive bone resorption and osteoporosis.

Overall, Parathyroid Hormone is a critical hormone that helps maintain mineral homeostasis and supports healthy bone metabolism.

The parathyroid glands are four small endocrine glands located in the neck, usually near or behind the thyroid gland. They secrete parathyroid hormone (PTH), which plays a critical role in regulating calcium and phosphate levels in the blood and bones. PTH helps maintain the balance of these minerals by increasing the absorption of calcium from food in the intestines, promoting reabsorption of calcium in the kidneys, and stimulating the release of calcium from bones when needed. Additionally, PTH decreases the excretion of calcium through urine and reduces phosphate reabsorption in the kidneys, leading to increased phosphate excretion. Disorders of the parathyroid glands can result in conditions such as hyperparathyroidism (overactive glands) or hypoparathyroidism (underactive glands), which can have significant impacts on calcium and phosphate homeostasis and overall health.

Parathyroid diseases refer to conditions that affect the parathyroid glands, which are small endocrine glands located in the neck, near or attached to the back surface of the thyroid gland. The primary function of the parathyroid glands is to produce and secrete parathyroid hormone (PTH), a crucial hormone that helps regulate calcium and phosphorus levels in the blood and bones.

There are four parathyroid glands, and they can develop various diseases, including:

1. Hyperparathyroidism: A condition where one or more parathyroid glands produce excessive amounts of PTH. This can lead to an imbalance in calcium and phosphorus levels, resulting in symptoms such as fatigue, weakness, bone pain, kidney stones, and increased risk of osteoporosis. Hyperparathyroidism can be primary (caused by a benign or malignant tumor in the parathyroid gland), secondary (due to chronic kidney disease or vitamin D deficiency), or tertiary (when secondary hyperparathyroidism becomes autonomous and continues even after correcting the underlying cause).
2. Hypoparathyroidism: A condition where the parathyroid glands do not produce enough PTH, leading to low calcium levels in the blood (hypocalcemia) and high phosphorus levels (hyperphosphatemia). Symptoms of hypoparathyroidism may include muscle spasms, tingling sensations in the fingers, toes, or lips, anxiety, cataracts, and seizures. Hypoparathyroidism can be caused by surgical removal of the parathyroid glands, autoimmune disorders, radiation therapy, or genetic conditions.
3. Parathyroid tumors: Abnormal growths in the parathyroid glands can lead to hyperparathyroidism. Benign tumors (adenomas) are the most common cause of primary hyperparathyroidism. Malignant tumors (carcinomas) are rare but can also occur, leading to more severe symptoms and a worse prognosis.
4. Parathyroid dysfunction in genetic disorders: Some genetic syndromes, such as multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2A (MEN2A), and hyperparathyroidism-jaw tumor syndrome (HPT-JT), can involve parathyroid gland abnormalities, leading to hyperparathyroidism or other related conditions.

Proper diagnosis and management of parathyroid disorders are crucial for maintaining optimal calcium homeostasis and preventing complications associated with hypocalcemia or hypercalcemia. Treatment options may include surgery, medication, dietary modifications, and monitoring hormone levels.

Parathyroid Hormone-Related Protein (PTHrP) is a protein that is encoded by the PTHLH gene in humans. It is structurally similar to parathyroid hormone (PTH) and was initially identified due to its role in humoral hypercalcemia of malignancy, a condition characterized by high levels of calcium in the blood caused by certain types of cancer.

PTHrP has a variety of functions in the body, including regulation of calcium and phosphate homeostasis, cell growth and differentiation, and bone metabolism. It acts through a specific G protein-coupled receptor called the PTH/PTHrP receptor, which is found in many tissues throughout the body, including bone, kidney, and cartilage.

In contrast to PTH, which is primarily produced by the parathyroid glands and regulates calcium levels in the blood, PTHrP is produced by many different types of cells throughout the body. Its expression is regulated in a tissue-specific manner, and its functions can vary depending on the context in which it is produced.

Overall, PTHrP plays important roles in normal physiology as well as in various disease states, including cancer, bone disorders, and developmental abnormalities.

Parathyroid Hormone Receptor Type 1 (PTH1R) is a type of G protein-coupled receptor that binds to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP). It is primarily found in bone and kidney cells.

The activation of PTH1R by PTH or PTHrP leads to a series of intracellular signaling events that regulate calcium homeostasis, bone metabolism, and renal function. In the bone, PTH1R stimulates the release of calcium from bone matrix into the bloodstream, while in the kidney, it increases the reabsorption of calcium in the distal tubule and inhibits phosphate reabsorption.

Mutations in the gene encoding PTH1R can lead to several genetic disorders, such as Blomstrand chondrodysplasia, Jansen metaphyseal chondrodysplasia, and hypoparathyroidism type 1B. These conditions are characterized by abnormalities in bone development, growth, and mineralization.

Parathyroid hormone (PTH) receptors are a type of cell surface receptor that bind to and respond to parathyroid hormone, a hormone secreted by the parathyroid glands. These receptors are found in various tissues throughout the body, including bone, kidney, and intestine.

The PTH receptor is a member of the G protein-coupled receptor (GPCR) family, which consists of seven transmembrane domains. When PTH binds to the receptor, it activates a signaling pathway that leads to increased calcium levels in the blood. In bone, activation of PTH receptors stimulates the release of calcium from bone matrix, while in the kidney, it increases the reabsorption of calcium from the urine and decreases the excretion of phosphate.

In the intestine, PTH receptors play a role in the regulation of vitamin D metabolism, which is important for calcium absorption. Overall, the activation of PTH receptors helps to maintain normal calcium levels in the blood and regulate bone metabolism.

Hyperparathyroidism is a condition in which the parathyroid glands produce excessive amounts of parathyroid hormone (PTH). There are four small parathyroid glands located in the neck, near or within the thyroid gland. They release PTH into the bloodstream to help regulate the levels of calcium and phosphorus in the body.

In hyperparathyroidism, overproduction of PTH can lead to an imbalance in these minerals, causing high blood calcium levels (hypercalcemia) and low phosphate levels (hypophosphatemia). This can result in various symptoms such as fatigue, weakness, bone pain, kidney stones, and cognitive issues.

There are two types of hyperparathyroidism: primary and secondary. Primary hyperparathyroidism occurs when there is a problem with one or more of the parathyroid glands, causing them to become overactive and produce too much PTH. Secondary hyperparathyroidism develops as a response to low calcium levels in the body due to conditions like vitamin D deficiency, chronic kidney disease, or malabsorption syndromes.

Treatment for hyperparathyroidism depends on the underlying cause and severity of symptoms. In primary hyperparathyroidism, surgery to remove the overactive parathyroid gland(s) is often recommended. For secondary hyperparathyroidism, treating the underlying condition and managing calcium levels with medications or dietary changes may be sufficient.

Parathyroidectomy is a surgical procedure for the removal of one or more of the parathyroid glands. These glands are located in the neck and are responsible for producing parathyroid hormone (PTH), which helps regulate the levels of calcium and phosphorus in the body.

Parathyroidectomy is typically performed to treat conditions such as hyperparathyroidism, where one or more of the parathyroid glands become overactive and produce too much PTH. This can lead to high levels of calcium in the blood, which can cause symptoms such as weakness, fatigue, bone pain, kidney stones, and mental confusion.

There are different types of parathyroidectomy procedures, including:

* Partial parathyroidectomy: removal of one or more, but not all, of the parathyroid glands.
* Total parathyroidectomy: removal of all four parathyroid glands.
* Subtotal parathyroidectomy: removal of three and a half of the four parathyroid glands, leaving a small portion of one gland to prevent hypoparathyroidism (a condition where the body produces too little PTH).

The choice of procedure depends on the underlying condition and its severity. After the surgery, patients may need to have their calcium levels monitored and may require calcium and vitamin D supplements to maintain normal calcium levels in the blood.

Hypercalcemia is a medical condition characterized by an excess of calcium ( Ca2+ ) in the blood. While the normal range for serum calcium levels is typically between 8.5 to 10.2 mg/dL (milligrams per deciliter) or 2.14 to 2.55 mmol/L (millimoles per liter), hypercalcemia is generally defined as a serum calcium level greater than 10.5 mg/dL or 2.6 mmol/L.

Hypercalcemia can result from various underlying medical disorders, including primary hyperparathyroidism, malignancy (cancer), certain medications, granulomatous diseases, and excessive vitamin D intake or production. Symptoms of hypercalcemia may include fatigue, weakness, confusion, memory loss, depression, constipation, nausea, vomiting, increased thirst, frequent urination, bone pain, and kidney stones. Severe or prolonged hypercalcemia can lead to serious complications such as kidney failure, cardiac arrhythmias, and calcification of soft tissues. Treatment depends on the underlying cause and severity of the condition.